Skip to content

Author

Kaili Dong

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Timosaponin AⅢ and Gefitinib Synergistically Inhibit NSCLC by Targeting RAGE/AKT/NF-κB/VEGF Pathway.

INTRODUCTION EGFR tyrosine kinase inhibitors (EGFR-TKIs) are the standard therapy for EGFR-mutated advanced Non-Small Cell Lung Cancer (NSCLC). Gefitinib (GEF), as a first-generation EGFR-TKI, has made significant progress in the treatment of advanced lung cancer. However, acquired resistance leading to treatment failu...

Meng-Fei Chen, Ting Xu, Hui-Ting Peng et al. · 0 citations
Aug 2026

Design, synthesis, and antitumor evaluation of celastrol derivatives targeting PRDX3.

In vivo efficacy evaluation demonstrated that 10d exhibited significantly superior tumor suppression in a subcutaneous xenograft model of H1975 tumors compared to celastrol, without causing notable systemic toxicity such as significant body weight loss.

Yu-Chi Zhao, Han-Shuang Cai, Li-Juan Zuo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.